Royalty Pharma Plc Stock Price, News & Analysis

The board of directors of Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.20 per Class A ordinary share for the second quarter of 2023. This dividend will be distributed on June 15, 2023, to shareholders recorded by the close of business on May 19, 2023. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties, collaborating across the industry to fund innovation. Its portfolio includes royalties from over 35 commercial products like Vertex’s Trikafta and AbbVie’s Imbruvica, among others. The company plays a pivotal role in funding both late-stage clinical trials and acquiring existing royalties, supporting advancements in biopharmaceuticals.

Royalty Pharma (Nasdaq: RPRX) has announced its plan to report first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. A conference call, available via webcast, will be held at 8:00 a.m. ET on the same day.

The company, established in 1996, is recognized as the largest buyer of biopharmaceutical royalties, funding innovation across the industry. Royalty Pharma collaborates with various organizations, including academic institutions and pharmaceutical companies, and currently holds a portfolio of royalties on over 35 commercial products, which includes notable therapies such as Vertex’s Trikafta and Biogen’s Tysabri.

Royalty Pharma plc (Nasdaq: RPRX) has authorized a share repurchase program of up to $1.0 billion for its Class A ordinary shares, with shareholder approval valid through June 2027. CEO Pablo Legorreta also plans to purchase an additional $50 million of these shares. This initiative reflects confidence in Royalty Pharma's growth potential and solid balance sheet, boosted by recent Biohaven-related payments. The company targets capital deployment of $10 to $12 billion over the next five years to invest in life sciences innovation while creating shareholder value.

Royalty Pharma has acquired an interest in PureTech’s royalty from Karuna Therapeutics for its therapy, KarXT, valued at up to $500 million. This includes $100 million upfront and potentially $400 million based on milestones. PureTech maintains its 3.1% equity stake in Karuna and will receive milestone payments and a share of sublicense revenues. The acquisition offers non-dilutive funding for PureTech’s pipeline, which includes five clinical-stage candidates expected by year-end.

Royalty Pharma (RPRX) announced a significant adjustment to its 2023 financial guidance, now expecting Adjusted Cash Receipts between $2,850 million and $2,950 million, up from previous estimates of $2,375 million to $2,475 million. This change follows a $475 million milestone payment from Pfizer after the FDA approved Zavzpret, a new migraine treatment. Royalty Pharma will collect royalties from both Zavzpret and Nurtec ODT sales. The guidance assumes no unforeseen adverse events and may be adjusted for new royalty transactions.

Royalty Pharma (Nasdaq: RPRX) has appointed Ashwin Pai, M.D., as Executive Vice President, Investments effective April 2023. He joins from Morgan Stanley, bringing nearly two decades of experience in biotechnology investment banking, having led major mergers and acquisitions. Ashwin's role will focus on sourcing and executing transactions, enhancing Royalty Pharma’s position within the life sciences sector, particularly on the West Coast. The firm, established in 1996, is a leading funder of biopharmaceutical innovation, holding royalties on over 35 commercial products, including therapies from Vertex and Biogen.

Royalty Pharma (Nasdaq: RPRX) reported Q4 and full year 2022 results showcasing strong financial performance. Net cash from operating activities reached $570 million, reflecting a 16% increase for the quarter and 6% for the year. Adjusted Cash Receipts surged 96% to $1,064 million in Q4 and 31% to $2,789 million for the year, driven by a $458 million payment from Pfizer’s Biohaven acquisition. For 2023, the company expects Adjusted Cash Receipts between $2,375 million and $2,475 million, excluding potential milestone payments. Royalty acquisitions in 2022 totaled up to $3.5 billion, bolstering its growth outlook.